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Abstract: The bark, seeds, fruits and leaves of the genus Fraxinus (Oleaceae) which contain a
wide range of phytochemicals, mostly secoiridoid glucosides, have been widely used in folk
medicine against a number of ailments, yet little is known about the metabolism and uptake of
the major Fraxinus components. The aim of this work was to advance in the knowledge on the
bioavailability of the secoiridoids present in a Fraxinus angustifolia Vahl seed/fruit extract using
both targeted and untargeted metabolomic analyses. Plasma and urine samples from nine healthy
volunteers were taken at specific time intervals following the intake of the extract and analyzed
by UPLC-ESI-QTOF. Predicted metabolites such as tyrosol and ligstroside-aglycone glucuronides
and sulfates were detected at low intensity. These compounds reached peak plasma levels 2 h
after the intake and exhibited high variability among the participants. The ligstroside-aglycone
conjugates may be considered as potential biomarkers of the Fraxinus secoiridoids intake. Using
the untargeted approach we additionally detected phenolic conjugates identified as ferulic acid and
caffeic acid sulfates, as well as hydroxybenzyl and hydroxyphenylacetaldehyde sulfate derivatives
which support further metabolism of the secoiridoids by phase I and (or) microbial enzymes.
Overall, the results of this study suggest low uptake of intact secoiridoids from a Fraxinus angustifolia
Vahl extract in healthy human volunteers and metabolic conversion by esterases, glycosidases, and
phase II sulfo- and glucuronosyl transferases to form smaller conjugated derivatives.
Keywords: tyrosol; ligstroside-aglycone; UPLC-ESI-QTOF; absorption; metabolism; phase II
conjugation
1. Introduction
The genus Fraxinus (Oleaceae) which contains a wide range of phytochemicals, mostly
secoiridoid glucosides, coumarins and phenylethanoids, but also some flavonoids, benzoquinones,
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indole derivatives and simple phenolics has been commonly used in traditional medicine against
various inflammatory diseases, infections, constipation, as a diuretic and as a hepatoprotective
agent [1]. Additionally, an extract produced from the seeds/fruits of Fraxinus has been shown to
moderate body weight gain, body fat, glucose and insulin levels, fatty liver incidence as well as blood
pressure in various animal models of obesity, diabetes and hypertension [2–5] supporting potential
beneficial properties of Fraxinus against metabolic disorders. These beneficial effects were observed
with doses ranging between 100 and 200 mg per kg of body weight per day, corresponding to a
Human Equivalent Dose (HED = animal dose in mg/kg ˆ (animal weight in kg/human weight
in kg)0.33) of ~1.0 g/day for a 60 kg person. Notably, the acute administration of 1 g of the Fraxinus
extract first evidenced the reduction of glycemia in healthy humans [6] and the daily administration
of 1 g of the Fraxinus extract for three weeks in elderly overweight/obese subjects resulted in a
significantly lower incremental glucose area under the curve, lower 2 h blood glucose levels and
modified levels of fructosamine and adiponectin:leptin ratio [7]. This Fraxinus extract, prepared
using a patented extraction protocol [8], was reported to contain a standardized amount (~10%) of
the secoiridoid glycoside nuzhenide (CAS registry number 60037-39-0) plus the dimeric secoiridoid
glycoside GL3 (glycosylated esters of tyrosol and elenolic acid; CAS registry number 39011-92-2)
(Figure 1). These two compounds were shown to activate peroxisome proliferator-activated receptor
alpha (PPARα) and to inhibit adipocyte differentiation in cultured adipocytes providing a potential
molecular mechanism underlying the metabolic regulatory activity of the Fraxinus extract [9]. These
secoiridoids have thus been proposed as the main bioactive constituents of the extract potentially
responsible for its beneficial effects [4,6,9] but the biological effects of these compounds within the
organism depend largely on their metabolism and uptake from the gastrointestinal tract.
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Figure 1. Chemical structures of the main secoiridoid constituents (nuzhenide and GL3) found in the 
Fraxinus angustifolia Vahl extract and of the specific metabolites detected in plasma and urine after the 
intake. The fragments originated from the hydrolysis of the secoiridoids are marked in red (tyrosol 
and ligstroside-aglycone). The derivatives produced by phase II conjugation are shown in blue color. 
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Figure 1. Chemical structures of the main secoiridoid constituents (nuzhenide and GL3) found in the
Fraxinus angustifolia Vahl extract and of the specific metabolites detected in plasma and urine after the
intake. The fragm nts originated from the hy rolysis of th secoiridoids are marked in red (tyrosol
and ligstroside-aglycone). The derivatives produced by phase II conjugation are shown in blue color.
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The bioavailability of other secoiridoids from olive oil [10–12] and olive leaf extracts [13–16]
that belong to the same Oleaceae family as Fraxinus have been reported but, to date and to the
best of our knowledge, there was no information on the bioavailability, the type of metabolites
formed and the pharmacokinetics of nuzhenide, GL3 and other secoiridoids present in the Fraxinus
extract. The characterization of in vivo circulating metabolites derived from the intake of plant dietary
phytochemicals remains an essential step for the identification of the actual bioactive molecules
and for the understanding of the mechanisms underlying the beneficial properties of these plant
compounds. However, unravelling the metabolic conversion of plant dietary bioactive compounds
and identifying their derived metabolites in humans remains an intricate and challenging task.
Metabolomics study global changes in the entire metabolite set of certain cells, tissues, organs and
organisms. It combines strategies to identify and quantify metabolites using sophisticated analytical
technologies (different chromatographic separation techniques, such as liquid or gas chromatography
coupled to mass spectrometry detection system) with the application of statistical and multi-variate
methods for the extraction of information and data interpretation. The application of metabolomics
in food systems (called as “food metabolomics” or “foodomics”) is a very powerful technology to
further progress in the elucidation and understanding of the metabolism and absorption of dietary
compounds [17]. By providing highly sensitive and specific metabolic profiles in body fluids and
tissues, it allows for the identification of potential bioactive metabolites and biomarkers of exposure
to diet compounds [18]. Two ways of identifying metabolites have been developed: (i) the targeted
approach which involves the selection of specific candidates that are likely to appear in the biological
samples [19] and (ii) the untargeted approach that uses advanced analytical tools to extract unknown
information of the metabolome from large data sets [20–22].
The aim of this pilot study was to investigate the metabolic fate of the main secoiridoids
present in a Fraxinus angustifolia Vahl seed/fruit extract in a group of healthy volunteers. Using
an UPLC-ESI-QTOF-MS, we searched for specific anticipated metabolites (targeted metabolomics)
as well as for other non-predicted metabolites (untargeted metabolomics) that appear in the urine
and plasma of the volunteers following the consumption of 1 g of the extract.
2. Results and Discussion
2.1. Fraxinus Extract Content in Secoiridoids
The UV chromatographic profile of the phenolic compounds extracted from the
Fraxinus angustifolia extract used in this study is shown in Figure 2. We confirmed that the two
major polyphenolic components, the secoiridoid glucosides nuzhenide (peak 8) and GL3 (peak 15),
were present and amounted up to 5.92% ˘ 0.14% and 4.75% ˘ 0.09%, respectively (total quantity:
10.67% ˘ 0.23%). Various other compounds were also detected in the extract based on their mass
[M ´ H]´, the MS/MS fragmentation pattern and data available in the literature (Table 1) [1,4].
Most of them were secoiridoid glucosides such as salidroside, oleoside, oleoside-11-methyl ester,
glucosylformoside, excelside B, GL5 and other isomers of nuzhenide and GL3. These compounds
contain as part of their molecular structure: tyrosol (4-hydroxyphenyl ethylalcohol), elenolic acid
and (or) elenolic acid linked to tyrosol (ligstroside-aglycone) (Figure 1). Other secoiridoids like
nuzhenide 11-methyl oleoside (isomer of GL3) and nuzhenide di(11-methyloleoside), previously
described in olive seeds [23], were first time tentatively identified in the Fraxinus extract.
We also detected various compounds displaying a UV spectrum similar to that typical of
hydroxycinnamic acid as well as verbascoside (ester of hydroxytyrosol, caffeic acid and the sugar
α-L-rhamnopyranosyl-(1-3)-β-D-glucopyranose).
To understand the potential metabolic effects of the compounds present in the Fraxinus extract
we need to determine their bioavailability and thus, we next investigated the bioavailability of the
main secoiridoid glucosides identified in the extract using a targeted approach.
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Figure 2. HPLC-UV (260 nm) chromatogram of the Fraxinus angustifolia Vahl seed/fruit extract used 
in the study. 
Table 1. Compounds identified in the Fraxinus angustifolia extract used in this study. 
Peak Compounds Rt (UV) [M − H]− MS/MS 
1 Salidroside 16.60 299 179,119 
2 Hydroxycinnamic acid derivative 16.92 487 295, 179, 135 
3 Oleoside 19.70 389 371, 345, 209, 179 
4 Oleoside 11-methyl ester 22.63 403 223, 179 
5 Hydroxycinnamic acid derivative 21.75 369 207, 192, 179 
6 Verbascoside 31.45 623 461, 315, 251  
7 Nuzhenide isomer 31.75 685 523, 453, 421, 299, 223 
8 Nuzhenide 33.28 685 523, 453, 421, 299, 223 
9 Nuzhenide isomer 34.72 685 523, 453, 421, 299, 223 
10 1-O-β-D-Glucosylformoside 36.03 685 523, 453, 385, 299, 223 
11 Nuzhenide derivative 37.01 727 685, 565, 523, 453, 341, 299 
12 Excelside B 37.61 685 565, 361, 291, 260 
13 GL3 isomer * 41.06 1071 909, 685, 523, 385 
14 GL3 isomer * 41.45 1071 909, 771, 685, 609, 421 
15 GL3 42.20 1071 909, 771, 685, 453, 385 
16 GL3 isomer * 43.36 1071 909, 685, 478, 361 
17 Nuzhenide di (11-methyloleoside) 44.96 1457 1157, 1071, 934, 771, 685 
18 GL5 isomer 48.70 909 771, 747, 523, 361, 259 
19 GL5 isomer 49.77 909 771, 747, 645, 523, 361 
* Some of GL3 isomers could correspond to nuzhenide 11-methyloleoside. 
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Table 1. Compounds identified in the Fraxinus angustifolia extract used in this study.
Peak Compounds Rt (UV) [M ´ H]´ MS/MS
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2 Hydroxycinnamic acid derivative 16.92 487 295, 179, 135
3 Oleoside 19.70 389 371, 345, 209, 179
4 Oleoside 11-methyl ester 22.63 403 223, 179
5 Hydroxycinnamic acid derivative 21.75 369 207, 192, 179
6 Verbascoside 31.45 623 461, 315, 251
7 Nuzhenide isomer 3 . 685 523, 453, 421, 299, 223
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2.2. Fraxinus Extract Derived Specific Plasma and Urine Metabolites: Targeted Analysis
The targeted approach involves searching for a selection of predicted metabolites that are likely
to appear in plasma and urine. Although scarce, data about absorption and metabolism of oleuropein,
a secoiridoid glycoside (ester of hydroxytyrosol and elenolic acid linked to glucose) present in olive
leaf extracts, were useful to develop the targeted analysis. It has been reported that oleuropein
was absorbed in very small quantities as such and also conjugated as glucuronide [13,14,24].
The predominant circulating metabolites were oleuropein-aglycone derivatives and the conjugates
(glucuronide, sulfate and methylated) of hydroxytyrosol suggesting extensive hydrolysis and
phase II conjugation of the parent compound [13–16]. Similar metabolites were observed after
the intake of olive oil, a foodstuff rich in oleuropein-aglycone [10,11]. Based on these results, we
specifically searched for a range of metabolites (Supplementary Table S1) covering the parent original
compounds, their aglycones, a number of potential fragments and the corresponding phase II
derivatives of all of them. None of the secoiridoid glucosides present in the Fraxinus extract were
detected in the urine and plasma samples indicating that the parent original compounds may not be
directly absorbed and must undergo some metabolic conversion. Similarly to the case of oleuropein,
we found that the main circulating metabolites following the intake of the Fraxinus extract were
the conjugates of the hydrolysis products of the parent compounds: a glucuronide and two sulfate
conjugates of tyrosol as well as a glucuronide and a sulfate conjugate of the ligstroside-aglycone
(Table 2). The molecular formulae of these metabolites were obtained with high score (>91) and
low error (<3.8 ppm). MS/MS spectra of tyrosol conjugates showed a characteristic fragment at
m/z 137.0606 indicative of a tyrosol moiety while a fragment ion at m/z 361.1288 representative
of a ligstroside-aglycone moiety appeared in the ligstroside-aglycone conjugates. Fragments at
m/z 79.9574 and 175.0246 were indicative of sulfate and glucuronic acid moiety respectively.
Table 2. Targeted analysis: metabolites detected in the urine and plasma samples of the volunteers
following the consumption of the Fraxinus angustifolia extract. All the metabolites were present at
low intensity.
Compounds RetentionTime (min)
m/z
Experimental Score Error
Molecular
Formulae MS/MS Fragments
Tyrosol glucuronide 5.30 313.0937 91.75 ´3.13 C14H18O8 137.0608, 175.0247
Tyrosol sulfate 1 5.79 217.0168 96.09 3.80 C8H10O5S 137.0604, 79.9572
Tyrosol sulfate 2 13.00 217.0174 95.35 1.78 C8H10O5S 137.0606, 79.9574
Ligstroside-aglycone * glucuronide 14.66 537.1613 97.9 ´0.05 C25H30O13 361.1288, 175.0246
Ligstroside-aglycone * sulfate 15.02 441.0868 95.6 ´1.74 C19H22O10S 361.1295, 79.9577
* Ligstroside-aglycone (elenolic acid-tyrosol).
These results provide the first evidence of the hydrolysis of the secoiridoids nuzhenide and GL3
and possibly of other minor secoiridoids (salidroside, glucosylformoside, excelside A and B, GL3 and
GL5 isomers) present in the Fraxinus extract via the loss of glucose moieties (Figure 1). This hydrolysis
might be mediated by the host and (or) microbial glycosidases and (or) esterases [25,26] followed by
phase II glucuronidation or sulfation of the aglycone molecules. The extracted ion chromatograms
(EICs) of the four metabolites in plasma samples at time 0 and 2 h and in urine samples at 0 and 8 h
are further illustrated in Figure 3.
Since standards for these compounds were not available, we were not able to accurately quantify
the levels of the detected metabolites. However, using relative peak areas (relative area = (peak area
metaboliteˆ 100/peak area IS)) we were able to plot the plasma and urine pharmacokinetic behavior
of each metabolite. Compounds identified in urine were quantified after adjustment for the volume
of urine produced. The absorption-time profiles in plasma and excretion-time profiles in urine for
each metabolite are shown in Figures 4a and 5a, respectively (mean values ˘ SD).
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Figure 3. Extracted Ion Chromatograms (EICs) of the main targeted metabolites identified in (a) 
plasma samples (time 0 vs. 2 h) and (b) urine samples (time 0 vs. 8 h). (* indicate peaks corresponding 
to the metabolites identified for each mass in Table 2). 
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Figure 4. (a) Plasma levels-time courses of the targeted metabolites detected. Values are means of nine 
volunteers with SD shown by vertical bars (1 and 2 correspond to two isomers of tyrosol sulfate);  
(b) Inter-individual variability in the content of the targeted metabolites observed in plasma 2 h after the 
consumption of the Fraxinus angustifolia Vahl extract. Differences between maximum and minimum 
values are indicated. All results are shown as relative peak areas (relative area = (peak area metabolite 
× 100/peak area internal standard)). 
Figure 4. (a) Plasma levels-time courses of the targeted metabolites detected. Values are means of
nine volunteers with SD shown by vertical bars (1 and 2 correspond to two isomers of tyrosol sulfate);
(b) Inter-individual variability in the content of the targeted metabolites observed in plasma 2 h
after the consumption of the Fraxinus angustifolia Vahl extract. Differences between maximum and
minimum values are indicated. All results are shown as relative peak areas (relative area = (peak area
metabolite ˆ 100/peak area internal standard)).
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Figure 5. (a) Urine concentration-time courses of the targeted metabolites detected. Values are means 
of nine volunteers with SD shown by vertical bars (1 and 2 correspond to two isomers of tyrosol sulfate); 
(b) Inter-individual variability in the content of the targeted metabolites observed in urine collected 
during the first 8 h after the consumption of the Fraxinus angustofolia Vahl extract. Differences between 
maximum and minimum values are shown. All results are shown as peak areas (relative area = (peak 
area metabolite × 100/peak area internal standard)). 
Our results evidenced that the secoiridoid metabolites derived from the Fraxinus angustifolia extract 
reached their maximum levels in plasma 2 h after the intake, i.e., slightly delayed in comparison with 
the maximum peak concentration for hydroxytyrosol and oleuropein conjugates (within the 35–75 min 
post-ingestion of olive leaf extract) [13,16]. The tyrosol sulfates were still detected in plasma at 24 h 
whereas the ligstroside-aglycone sulfate was not detected any longer after 4 h. In urine, all the 
metabolites examined were detected mostly at 8 h after the intake of the extract, similarly to the 
excretion of hydroxytyrosol and oleuropein conjugates [13,16]. Some metabolites, especially those 
Figure 5. (a) Urine concentration-time courses of the targeted metabolites detected. Values are means
of nine volunteers with SD shown by vertical bars (1 and 2 correspond to two isomers of tyrosol
sulfate); (b) Inter-individual variability in the content of the targeted metabolites observed in urine
collected during the first 8 h after the consumption of the Fraxinus angustofolia Vahl extract. Differences
between maximum and minimum values are shown. All results are shown as peak areas (relative
area = (peak area metabolite ˆ 100/peak area internal standard)).
Our results evidenced that the secoiridoid m tabolites derived from the Fraxinus angustifolia
extract reached their maximum levels in plasma 2 h after the intake, i.e., slightly delayed in
comparison with the maximum peak concentration for hydroxytyrosol and oleuropein conjugates
(within the 35–75 min post-ingestion of olive leaf extract) [13,16]. The tyrosol sulfates were still
detected in plasma at 24 h whereas the ligstroside-aglycone sulfate was not detected any longer after
4 h. In urine, all the metabolites examined were detected mostly at 8 h after the intake of the extract,
similarly to the excretion of hydroxytyrosol and oleuropein conjugates [13,16]. Some metabolites,
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especially those derived from tyrosol, continued appearing at 24 h. As it is the case for other
dietary polyphenols [27], the levels of all the examined metabolites exhibited a high inter-individual
variability as depicted in Figures 4b and 5b (individual values for each 2 h-plasma and 8 h-urine
metabolite after the intake of the Fraxinus extract, respectively). Differences between the maximum
and minimum levels of metabolites were up to 18-fold and 15-fold in plasma and 19-fold and 10-fold
in urine for tyrosol glucuronide and ligstroside-aglycone glucuronide, respectively. Generally, the
translation of beneficial metabolic effects of dietary polyphenols from pre-clinical animal models
to human intervention studies has shown inconsistent evidences possibly and partly due to the
variability in the metabolism and uptake of these compounds [28]. In the case of the Fraxinus extract
which has been shown to moderate fasting blood glucose (FBG) and insulin levels in rodent models
of obesity, intervention in obese and overweight subjects resulted in 2 h-blood glucose improvement
following an oral glucose tolerance test but not significant differences for FBG and insulin levels
were observed [7]. Small sample size and variability in the capacity of each volunteer to absorb and
metabolize the secoiridoids from the Fraxinus extract may contribute to explain the lack of current
significant mean effects in humans for those two metabolic biomarkers. Other factors such as gender
can influence the bioavailability of the secoiridoids as previously suggested for olive leaf extracts [13]
but a difference between male and female was not apparent in this study. The variability in the
bioavailability of the secoiridoids from the Fraxinus extract and the factors affecting it needs to be
further and critically assessed.
2.3. Untargeted Approach to Study Non-Predicted Secoiridoid Metabolites Appearing in Plasma and
Urine Samples
We further explored the appearance of other non-predicted potential metabolites directly
derived from the metabolic transformation of the secoiridoids in the plasma and urine samples of
the volunteers following the intake of the Fraxinus extract using an untargeted strategy that enables
the extraction of the required information from large data sets. Between 600 and 800 peaks in the
plasma samples and 500 and 2000 peaks in the urine samples were extracted by chromatographic
deconvolution. After alignment based on mass accuracy and retention time, 2360 unique entities in
plasma and 6216 in urine were identified. Filtering by frequency (data present in at least 50% of
the volunteers in at least one time-point) reduced the number of molecular features (MFs) to 681 in
plasma and 1243 in urine. The filtered features were then compared between the baseline samples
and the different time-points examined using one-way ANOVA yielding a total of 98 significantly
different features in plasma and 336 in urine (p < 0.05, fold-change cut-off = 2.0). Unsupervised PCA
was used to visualize these results into six well-discriminated groups in plasma (Figure 6a) and three
groups in urine (Figure 6b). The baseline samples resulted clearly separated from those samples taken
at the different time-points.
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Figure 6. Principal component analysis (PCA) scores plot of the plasma (a) and urine (b) samples of 
nine volunteers analyzed at baseline (control) and at different time-points after the intake of the 
Fraxinus angustifolia Vahl extract. 
The metabolites responsible for the discrimination of these time-points groups may be: (i) of 
exogenous origin, i.e., resulting from the absorption and metabolism of Fraxinus compounds but also 
from other compounds taken with the diet and (ii) of endogenous origin, i.e., metabolites that could be 
altered by the intake of the Fraxinus extract [20]. We concentrated our efforts towards the identification 
of those metabolites that were significantly increased following the ingestion of the extract and that 
may derive directly from the secoiridoids present in it. A total of 50 MFs in the plasma samples and  
52 MFs in the urine samples were found consistently at higher levels in the post-ingestion samples than 
in the baseline samples. Using their exact mass and MS/MS fragments we were able to tentatively 
identify seven compounds in the plasma and four compounds in the urine (Table 3) that showed high 
p(corr) values. Tyrosol sulfate in plasma and ligstroside-aglycone glucuronide both in plasma and 
urine, previously detected in the targeted analysis, were confirmed as significantly different offering 
partial validation of the untargeted approach. These results support that ligstroside-aglycone glucuronide 
may constitute a good candidate as a “biomarker of intake” for the Fraxinus extract since this metabolite 
is specifically originated from the secoiridoids present in the extract, was not present in the urine and 
plasma samples at baseline and was identified as one of the MFs that contribute to differentiate 
between the post ingestion time-point samples and the baseline samples (p(corr) = 0.00275 in plasma 
and 0.0108 in urine). We additionally detected the phenolic derivatives, ferulic acid and caffeic acid 
sulfate. Further, and in support of microbial metabolism of the Fraxinus secoiridoids, we were able to 
detect a significant rise in plasma and/or urine of the sulfate conjugates of the microbial metabolites 
4-hydroxybenzyl alcohol, 4-hydroxyphenylacetaldehyde and 3,4-dihydroxyphenylacetaldehyde 
(DOPAL). These metabolites may result from the fermentation of tyrosol and (or) hydroxytyrosol by fecal 
microbial metabolism [29,30]. These metabolites may derive from the fermentation of different dietary 
polyphenols and thus we cannot unequivocally relate them to the intake of the Fraxinus secoiridoids. 
The main objective of this study was to contribute to identify some of the metabolites circulating 
in vivo in humans following the intake of a Fraxinus angustifolia extract and that could be potentially 
involved in the metabolic regulatory effects attributed to this natural extract. We acknowledge that 
this is a preliminary study with a small number of volunteers and that future studies should include 
a larger number of participants to account for the variability in the human absorption and metabolism 
of plant bioactive compounds. Nevertheless we have shown that tyrosol conjugates constitute some 
of the main metabolites circulating in plasma after the intake of the extract. Since it has been reported 
that tyrosol moderates the levels of blood glucose and insulin in streptozotocin-induced diabetic rats [31] 
it is possible that the tyrosol conjugates may be partially involved in the glycemic regulatory effects 
associated with the consumption of the Fraxinus extract [2–4,6,7].
Figure 6. Principal component analysis (PCA) scores plot of the plasma (a) and urine (b) samples
of nine volunteers analyzed at baseline (control) and at different time-points after the intake of the
Fraxinus angustifolia Vahl extract.
The metabolites responsible for the discrimination of these time-points groups may be:
(i) of exogenous origin, i.e., resulti g from the absorption and metabolism of Fraxinus compounds
but also from oth r c mpounds take with the diet and (ii) of e doge us origin, i.e., metabolites
that could be altered by the intake of the Fraxinus extract [20]. We concentrated our efforts towards
the identification of those metabolites that were significantly increased following the ingestion of the
extract and that may derive directly from the secoiridoids present in it. A total of 50 MFs in the
plasma samples and 52 MFs in he urine s mples were found consistently at higher levels in the
post-ingestion samples than in the baseline samples. Using their exact mass and MS/MS fragments
we were able to tentatively identify seven compounds in the plasma and four compounds in the
urine (Table 3) that showed high p(corr) values. Tyrosol sulfate in plasma and ligstroside-aglycone
glucuronide both in plasma and urine, previously detected in the targeted analysis, were confirmed
as significantly different offeri g partial validatio of the untargeted a proach. These results support
that ligstroside-aglycone glucuronide may constitute a good candidate as a “biomarker of intake” for
the Fraxinus extract since this metabolite is specifically originated from the secoiridoids present in the
extract, was not present in the urine and plasma samples at baseline and was identified as one of the
MFs that contribute to differentiate between e post ingestion time-p int samples and the baseline
samples (p(c rr) = 0.00275 in plasma and 0.0108 in urine). We additionally et cted the phenolic
derivatives, ferulic acid and caffeic acid sulfate. Further, and in support of microbial metabolism of
the Fraxinus secoiridoids, we were able to detect a significant rise in plasma and/or urine of the sulfate
conjugates of the microbial metabolites 4-hydroxybenzyl alcohol, 4-hydroxyphenylacetaldehyde and
3,4-dihydroxyphenylacetaldehyde (DOPAL). These metabolites may result from the fermentation of
tyrosol and (or) hydroxytyrosol by fecal microbial metabolism [29,30]. These metabolites may derive
from the fermentation of different dietary polyphenols and thus we cannot unequivocally relate them
to the intake of the Fraxinus secoiridoids.
The main objec ive of his study w s to contribute to identify some of the met bolites irculating
in vivo in hum ns following the intake of a Fraxinus ngustifolia extract and that could be potentially
involved in the metabolic regulatory effects attributed to this natural extract. We acknowledge that
this is a preliminary study with a small number of volunteers and that future studies should include a
larger number of participants to account for the variability in the human absorption and metabolism
of plant bioactive compounds. Nevertheless we have shown that tyrosol conjugates constitute some
of the main metabolites circulating in plasma after the intake of the extract. Since it has been reported
that tyrosol moderates the levels of blood glucose and insulin in streptozotocin-induced diabetic
rats [31] it is possible that the tyrosol conjugates may be partially involved in the glycemic regulatory
effects associated with the consumption of the Fraxinus extract [2–4,6,7].
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Table 3. Metabolites significantly increased in the plasma and urine samples of the volunteers following the intake of Fraxinus extract and related to the family of
phenolic compounds: untargeted approach.
Exact Mass RetentionTime (min)
Error
(ppm) Score MS/MS
Molecular
Formula Tentatively Identified Metabolite Time-Points (h) * p(corr)
Plasma
259.9985 8.28 0.02 98.12 179.0352, 135.0455, 96.9592 C9H8O7S Caffeic acid sulfate 1, 2, 4, 8 3.85 ˆ 10´8
274.014 8.58 1.92 98.53 193.0505 C10H10O7S Ferulic acid sulfate 2, 4 1.70 ˆ 10´3
204.0087 10.41 3.98 94.87 123.0449, 79.9575 C7H8O5S 4-hydroxybenzyl alcohol sulfate 1 ,2, 4 3.50 ˆ 10´6
274.0142 10.98 2.01 97.79 193.0505 C10H10O7S Ferulic acid sulfate 1, 2 1.04 ˆ 10´15
216.0087 12.20 1.55 98.84 135.0047 C8H8O5S 4-hydroxyphenylacetaldehyde sulfate 2, 4 9.55 ˆ 10´6
218.024 13.01 2.3 97.58 137.0606, 122.0374, 79.9574 C8H10O5S Tyrosol sulfate 1, 2, 4 1.98 ˆ 10´12
538.1688 14.64 ´0.02 99.04 493.1712, 401.8835, 361.1288,175.0246, 153.0917, 113.0240 C25H30O13 Ligstroside-aglycone glucuronide 1, 2, 4, 8 2.75 ˆ 10
´3
Urine
232.0048 8.23 ´1.6 98.03 203.2221, 151.0399, 108.0213 C8H8O6S 3,4-dihydroxyphenylacetaldehyde(DOPAL)-sulfate * 8, 24 1.25 ˆ 10
´2
368.1114 8.39 ´0.63 98.69 193.0505,134.0376 C17H20O9 Ferulic acid derivative 8, 24 1.98 ˆ 10´3
274.0152 10.98 ´1.71 97.52 193.0508, 149.0243, 121.0285,93.0347, 65.0396 C10H10O7S Ferulic acid sulfate 8, 24 2.24 ˆ 10
´3
538.1688 14.65 ´0.02 99.04 493.1712, 401.8835, 361.1288,175.0246, 153.0917, 113.0240 C25H30O13 Ligstroside-aglycone glucuronide 8, 24 1.08 ˆ 10
´2
* Time points in which the metabolites were detected. The time-point exhibiting maximum concentration is underlined.
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Our results also show that the main secoiridoids present in the Fraxinus extract are not detected
in the plasma after the intake of a high dose (1 g) suggesting that these compounds are poorly
absorbed and might be retained in the intestine. It is widely known that the food matrix can
have a critical impact on the bioavailability of polyphenols [32] and thus, it is plausible that other
constituents present in the Fraxinus extract such as complex carbohydrates and proteins [8] may affect
the absorption of the secoiridoids. We further hypothesize that the secoiridoids may exert some of
their metabolic effects at the intestinal level, by modifying the microbiota composition and/or by
interacting with the intestinal barrier [28,33]. We cannot discard either that the other constituents
of the extract can contribute to the metabolic benefits of Fraxinus. These issues require further
investigation and point towards a potential prebiotic effect of the Fraxinus extract.
3. Experimental Section
3.1. Chemicals
Pure standards of nuzhenide and GL3 were synthetized and sent to us by Naturex S.A. (Avignon,
France). Stock solutions of both compounds were prepared in water (2000 ppm) and standard
mixtures were diluted in methanol (MeOH)/water (50/50, v/v) to a final concentration of 500 ppm.
Quercetin (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in MeOH (5000 ppm) and used as
internal standard (IS). MeOH and acetonitrile were from J. T. Baker (Deventer, The Netherlands) and
formic acid and HCl were from Panreac (Barcelona, Spain). All other chemicals and reagents were
of analytical grade. Milli-Q system (Millipore Corp., Bedford, MA, USA) ultrapure water was used
throughout the study.
3.2. Fraxinus Extract Characterization
The raw material used for the extract preparation was previously identified using a high pressure
thin-layer chromatographic method and reported as Fraxinus excelsior L. (common ash) [2–4,6–9]. The
whole aerial part of the plant containing the seeds has been now re-evaluated combining macroscopic
analyses, high pressure thin layer chromatography (HPTLC, CAMAG, Muttenz, Switzerland) and
DNA techniques (these analyses were conducted by Ms. Mélissa Feuillatre, Naturex botanist, using
authenticated DNA Fraxinus angustifolia Vahl fruit as the botanical reference). Further DNA-based
authentication by two independent laboratories (AuthenTechnologies LLC, Richmond, CA, USA and
DNA Gensee, Le Bourget du Lac, France) has confirmed that the plant material belongs to the specie
Fraxinus angustifolia Vahl (narrow-leaved ash). The fruits of Fraxinus angustifolia Vahl were collected
from the Demnat region in central Morocco (by Mr. Ahmed Sghir, Agricultural Engineer). The
corresponding voucher was assigned the voucher specimen identifier 1HAB0044#B020/019/A14;
Reference AU100815) and is deposited at Naturex Avignon (Avignon, France).
The F. angustifolia extract used in this study was prepared from the seeds and fruits, encapsulated
(334 mg per capsule) and kindly supplied by Naturex S.A. (Avignon, France, product code EA149251).
The full composition of the extract has been previously reported [8]. Briefly, the extract contains a
high proportion of carbohydrates (72.4 g/100 g) and small quantities of protein and total dietary
fiber (approximately 6 g/100 g each). It also contains relatively high concentrations of glucose and
sucrose (3.34 and 3.84 g/100 g, respectively). The extract was standardized to contain approximately
10 % of the secoiridoids, nuzhenide and GL3 using the extraction process described in the patent
US 8293292 [34].
The specific phenolic composition of the extract used in this study was monitored using
an HPLC-DAD-MS/MS (IT) system. The Fraxinus extract (20 mg) was dissolved with 1 mL of
MeOH/H2O (50/50, v/v), vortexed for 2 min and ultrasonicated for 10 min prior to centrifugation
at 3500ˆ g for 10 min. The supernatant was filtered (0.45 µm PVDF) before injection. Analyses
were carried out on an Agilent 1100 HPLC system equipped with a photodiode array detector
and an ion-trap mass spectrometer detector in series (Agilent Technologies, Waldbronn, Germany).
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The separation of phenolic compounds was achieved on a reverse phase LiChroCART C-18 column
(Merck, Darmstadt, Germany) (250 ˆ 4 mm, 4.5 µm particle size), operating at room temperature
and a flow rate of 0.8 mL/min. A sample volume of 10 µL was injected. The mobile phases used
were water with formic acid (1%) (phase A) and acetonitrile (phase B) and the solvent gradient was
as follows: 0 min, 1% B, 0 to 10 min, 1%–9% B; 10 to 48 min, 9%–35% B; 48 to 52 min, 35%–95% B;
52 to 54 min, 95%–1% B and maintained at 1 % for 6 min (total run = 60 min). The UV-Vis spectra were
acquired in the range of 200 to 600 nm. Compounds were monitored at 260 nm. Nitrogen was used
as drying and nebulising gas in the electrospray interface (ESI) with pressure at 65 psi, flow 11 L/min
and temperature 350 ˝C. MS and MS/MS spectra were recorded in negative mode in the range of
m/z 100–1500 with target mass of 700. Identification of compounds was carried out by their spectral
properties, molecular mass and literature information. The calibration curves of nuzhenide and GL3
were constructed from 1 ppm to 500 ppm in MeOH/water (50/50, v/v).
3.3. Human Intervention Study
This pilot study was conducted conformed to ethical guidelines outlined in the Declaration of
Helsinki and its amendments and was approved by the Research Ethical Committee of the Catholic
University of San Antonio (Murcia, Spain). Prior to their participation, the volunteers were informed
of the background, objectives, methodology, risks of the intervention, as well as of the type of results
and benefits expected and gave written informed consent. Inclusion criteria were as follows: young
(20–25 year old) healthy men and women (body mass index, BMI < 30 kg/m2), non-smoker and
non-alcohol consumers (ď30 g/day), with no-abnormal dietary habits or vitamin supplementation.
Participants were excluded if they were taking medication and/or had consumed antibiotics for
3 months prior to the intervention, or if they suffered from any hemostatic or metabolic disturbances,
gastrointestinal and/or cardiovascular diseases, or any other chronic disease. The only dietary
source known to contain some secoiridoids (mostly oleuropein, ligstroside and hydroxytyrosol [13])
is olives and derived products, such as olive oil. Since it has been reported that olive metabolites are
eliminated well within 24 h [13], the volunteers were instructed to avoid all olive products during the
three days previous to the study. Volunteers gathered in a room specifically designed for this purpose
for the duration of the intervention. A total of nine volunteers completed the study. This sample size
is comparable to previous studies in the field [11,13,20,22]. The characteristics of the participants are
summarized in Table 4.
Table 4. Summary of the demographic and anthropomorphic characteristics of the volunteers taking
part in the study. Data are shown as the mean value ˘ SD.
N 10
Gender (M/F) (4/6)
Age (years old) 23.5 ˘ 1.3
Weight (kg) (M) 81.0 ˘ 12.0
(F) 69.1 ˘ 7.2
BMI (kg/m2)
(M) 25.1 ˘ 2.8
(F) 21.5 ˘ 2.1
The sampling protocol is depicted in Figure 7. Blood (5 mL) was collected into heparinized tubes
from the antecubital arm vein: one sample at baseline (8.00 a.m. before Fraxinus intake, control) and
several samples at predetermined time points (1, 2, 4, and 8 h) following a single acute dose of the
Fraxinus extract in hard capsules (3 ˆ 334 mg) with a glass of water. This dose was chosen according
to that used in previous animal and human studies [2–7] reporting some metabolic beneficial effects.
The volunteers were asked to come back the following morning (8.00 a.m. before breakfast) for a
further 24 h blood sample extraction. Blood samples were centrifuged (3000ˆ g, 15 min) and plasma
was frozen prior to metabolites analysis. The participants were also given special containers for
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urine collection. They collected three urine samples: at baseline (taken the morning of the study
before Fraxinus intake) as well as the urine produced during the following 8 and 24 h after the
extract consumption. Total urine volume was measured and all urine samples were frozen until
further analysis.Molecules 2015, 20, page–page 
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Figure 7. Experimental design and sampling protocol. 
3.4. Urine and Plasma Samples Preparation 
Urine samples were thawed, rapidly vortexed to homogenize the sample, then centrifuged at 
14,000× g for 10 min and filtered (0.45 μm PVDF). Prior to injection, the samples were diluted (1:5) with 
acidified water (0.1% formic acid). Plasma samples were thawed and 200 μL mixed and extracted with 
600 μL ACN:formic acid (99.8:0.2, v/v) by vortexing for 2 min followed by ultrasonic bath for 10 min. 
The mixture was centrifuged at 14,000× g for 10 min and the supernatant was reduced to dryness in a 
speed vacuum concentrator. The dried samples were re-suspended in 200 μL of MeOH/water (50/50, 
v/v) plus 0.1% formic acid and filtered (0.45 μm PVDF filter) prior to analysis. Quercetin (IS) was 
added just before injection of both types of samples (final concentration 0.5 ppm). 
3.5. UPLC-ESI-QTOF MS Analysis of Plasma and Urine Samples 
The analyses were carried out using an Agilent 1290 Infinity LC system coupled to the 6550 
Accurate-Mass QTOF (Agilent Tecnologies, Waldbronn, Germany) with electrospray interface (Jet 
Stream Technology). Samples were injected (2 μL) on a reverse phase Poroshell 120 EC-C18 column 
(3 × 100 mm, 2.7 μm) (Agilent Tecnologies) operating at 30 °C and a flow rate of 0.4 mL/min. The 
mobile phases used were acidified water (0.1% formic acid) (Phase A) and acidified ACN (0.1% formic 
acid) (Phase B). Compounds were separated using the following gradient conditions: 0–10 min,  
1%–18% phase-B; 10–16 min, 18%–38% phase-B; 16–22 min, 38%–95% phase-B. Finally, the phase B 
content was returned to the initial conditions (1%) in 1 min and the column re-equilibrated for 5 min. 
The best conditions for the electrospray interface were: gas temperature 280 °C, drying gas 9 L/min, 
nebulizer 35 psi, sheath gas temperature 400 °C, sheath gas flow 12 L/min. Spectra were acquired in 
the range 100–1100 m/z in negative mode, fragmentor was 100 V and acquisition rate 1.5 spectra/s. 
Targeted MS/MS analyses were developed to add confidence to compound identification. MS/MS 
product ion spectra were collected at an m/z range of 50–800 using a retention time window of 1 min, 
an isolation window of 4.0 amu, collision energy of 20 V and an acquisition rate of 4 spectra/s. To assure 
the desired mass accuracy of recorded ions, continuous internal calibration was performed during 
analyses with the use of signals m/z 112.9855 (detected m/z [C2O2F3 − H]−) and 1033.9881 (detected m/z 
[C18H18O6N3P3F24 + TFA-H]−). Data were processed using the Mass Hunter Qualitative Analysis software 
(version B.06.00, Agilent Technologies). Two strategies were applied for the identification of metabolites: 
targeted and untargeted analysis. 
3.5.1. Targeted Metabolomics Analysis 
The target screening strategy consists of searching for a list of predicted compounds after MS full 
acquisition. The list was created taking into account the information available in the literature about the 
absorption and metabolism of other secoiridoids [13,16] or other families of phenolic compounds [35]. 
We first searched for the presence of the compounds originally found in the extracts (mainly 
secoiridoids glucosides) (Figure 1 and Table 1) as well as possible compounds that may derive from 
the hydrolysis of these glucosides, especially those that may be released by the action of glycosidases, 
Figure 7. Experi ental design and sa pling protocol.
3.4. Urine and Plasma Samples Preparation
Urine samples were thawed, rapidly vortexed to homogenize the sample, then centrifuged at
14,000ˆ g for 10 min and filtered (0.45 µm PVDF). Prior to injection, the samples were diluted (1:5)
with acidified water (0.1% formic acid). Plasma samples were thawed and 200 µL mixed and extracted
with 600 µL ACN:formic acid (99.8:0.2, v/v) by vortexing for 2 min followed by ultrasonic bath for
10 min. The mixture was centrifuged at 14,000ˆ g for 10 min and the supernatant was reduced
to dryness in a speed vacuum concentrator. The dried samples were re-suspended in 200 µL of
MeOH/water (50/50, v/v) plus 0.1% formic acid and filtered (0.45 µm PVDF filter) prior to analysis.
Quercetin (IS) was added just before injection of both types of samples (final concentration 0.5 ppm).
. . - I- l sis f l s ri e les
l s s were carried out using an Agilent 1290 Infinity LC system coupled to the
6550 Accurate-Mass QTOF (Agilent Tecnologies, Waldbronn, Germany) with electrospray interface
(Jet Stream Technology). Samples were injected (2 µL) on a reverse phase Poroshell 120 EC-C18
column (3ˆ 100 m , 2.7 µm) (Agilent Tecnol gi s) oper ting at 30 ˝C and a flow rate of 0.4 L/min.
The mobile phases used were acidified water (0.1% formic acid) (Phase A) and acidified ACN
(0.1% formic acid) (Phase B). Compounds were separat d using the following gradie t conditions:
0–10 min, 1%–18% phase-B; 10–16 min, 18%–38% phase-B; 16–22 min, 38%–95% phase-B. Finally,
the phase B conte t was returned t the initial conditions (1%) in 1 min a d the column re-equilibrated
for 5 min.
The best conditions for the electrospray interface were: gas temperature 280 ˝C, drying gas
9 L/min, nebulizer 35 psi, sheath gas temperature 400 ˝C, sheath gas flow 12 L/min. Spectra
were acquired in the range 100–1100 m/z in negative mode, fragmentor was 100 V and acquisition
rate 1.5 spectra/s. Targeted MS/MS analyses were developed to add confidence to compound
identification. MS/MS product ion spectra were collected at an m/z range of 50–800 using a retention
time window of 1 min, an is lation window of 4.0 amu, collisio energy of 20 V and an acquisition rate
of 4 spectra/s. To assure the desired mass accuracy of recorded ions, continuous internal calibration
was performed during analyses with the use of signals m/z 112.9855 (detected m/z [C2O2F3 ´ H]´)
and 1033.9881 (detected m/z [C18H18O6N3P3F24 + TFA-H]´). Data were processed using the Mass
Hunter Qualitative Analysis software (version B.06.00, Agilent Technologies). Two strategies were
applied for the identification of metabolites: targeted and untargeted analysis.
22215
Molecules 2015, 20, 22202–22219
3.5.1. Targeted Metabolomics Analysis
The target screening strategy consists of searching for a list of predicted compounds after MS
full acquisition. The list was created taking into account the information available in the literature
about the absorption and metabolism of other secoiridoids [13,16] or other families of phenolic
compounds [35]. We first searched for the presence of the compounds originally found in the extracts
(mainly secoiridoids glucosides) (Figure 1 and Table 1) as well as possible compounds that may
derive from the hydrolysis of these glucosides, especially those that may be released by the action
of glycosidases, i.e., tyrosol and ligstroside-aglycone (Figure 1). We then searched for the presence
of compounds potentially derived from the metabolic transformation of the parent glucosides and
aglycone fragments. We specifically searched for phase I and phase II conjugates (glucuronide,
sulfate, sulfoglucuronide, methyl-derivatives and hydroxylated derivatives) of all the compounds.
The complete list of the investigated metabolites, molecular formula and exact mass is included in
Supplementary Table S1. Screening was based on mass filtering at the exact mass of the metabolite
investigated using narrow mass extraction windows (0.01 m/z). The identification was possible with
the support of the information attained in the QTOF-MS acquisition mode that provides potential
molecular formulae for the compounds based on the accurate mass and isotopic pattern.
3.5.2. Untargeted Metabolomics Analysis Steps
To explore the potential presence in plasma and urine samples of other non-anticipated
metabolites derived from the metabolic transformation of the secoiridoids, we developed and
applied an untargeted metabolomics approach. To cope with the complexity of the results obtained
by UPLC-QTOF measurements, date pre-processing and statistical analyses were implemented.
Initial data processing was carried out using the Molecular Feature Extraction (MFE) algorithm.
Ions were extracted as molecular features (MFs) characterized by retention time, intensity of the
chromatographic peak and accurate mass. For the extraction procedure (both in plasma and urine
samples), the minimum absolute abundance was set at 5000 counts and the minimum number of
ions at 2. Further, the m/z range was between 100 and 1500 and the time range between 0.5 and
20 min. Data files in compound exchange format (.cef files) were created for each sample and exported
into the Mass Profiler Professional (MPP) software package (version B.12.01, Agilent Technologies,
Santa Clara, CA, USA) for further processing. Alignment of retention time and m/z values was
carried out across the samples using a tolerance window of 0.2 min and 15 ppm of the observed
m/z + 2 mDa. To reduce the dimensionality of the data prior to statistical analyses and to focus
on the objective of the analysis, all the MFs that were not present in at least 50% of the samples
(volunteers) in at least one group (time-point after the FXE intake) were removed. Only those features
present in 5 out of 9 volunteers in at least one time were analyzed. Using one-way ANOVA (p < 0.05,
Benjamini-Hochberg false discovery rate (FDR) multiple testing correction) and a fold-change cut-off
of 2.0 we generated a list of compounds that differed significantly between groups (time-points).
The final list of selected ions was subjected to unsupervised principal component analysis (PCA)
to visualize differences in metabolite profiles at different times after the intake of FXE. Since this
study was mainly focused on the search for metabolites potentially derived from the secoiridoids,
all the metabolites with peak intensity higher in the control than after the ingestion (down-regulated)
were not considered. Determination of the molecular formula and tentative identification of the rest
of compounds (up-regulated) was carried out using accurate mass measurement of full single MS
spectra and additional information obtained by MS/MS analyses. These data were compared to
those registered in various databases such as METLIN, KEGG LIGAND and Human Metabolome
Database (HMD).
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4. Conclusions
In this study we have applied targeted and non-targeted metabolomic approaches to determine
absorbed metabolites following acute ingestion of a Fraxinus angustifolia seed/fruit extract in
human healthy volunteers. LC-QTOF MS analyses of urine and plasma samples revealed limited
bioavailability of the intact secoiridoids present in the extract and further metabolism by glycosidases,
esterases and phase II conjugation enzymes to form mostly tyrosol and ligstroside-aglycone
conjugates. The ligstroside-aglycone conjugates may constitute a good biomarker of exposure to the
Fraxinus extract. The appearance in plasma and urine of some phenolic derivatives suggest additional
metabolism by phase I and (or) microbial enzymes. Further studies are needed to clarify the metabolic
conversion of secoiridoids from Fraxinus and to advance the knowledge of its metabolic benefits and
mechanisms of action.
Supplementary Materials: Supplementary materials can be accessed at: http://www.mdpi.com/1420-3049/
20/12/19845/s1.
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